Complete Remission by Imatinib Mesylate (Glivec) in a Child Relapsing with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph (+) ALL) after Unrelated Donor Stem Cell Transplantation / 대한소아혈액종양학회지
Korean Journal of Pediatric Hematology-Oncology
;
: 110-114, 2003.
Article
in Korean
| WPRIM
| ID: wpr-115284
ABSTRACT
The prognosis of patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph ALL) who relapsed after allogeneic stem cell transplantation (allo-SCT) is poor. Imatinib mesylate (Glivec (R) ) is an inhibitor of the ABL tyrosine kinase with potent antileukemic activity in advanced Ph ALL. The clinical effects of imatinib on Ph ALL recurring after allo-SCT have not been established. We describe the clinical activity of imatinib in a 7 year-old boy with Ph ALL relapsing after unrelated donor stem cell transplantation. Imatinib as a single agent resulted in rapid elimination of leukemic cells with ensuing prolonged neutropenia and thrombocytopenia. Subsequent hematological recovery by donor-derived cells was associated with grade 3 graft-versus-host disease (GvHD), which responded to cyclosporine A and steroid. Imatinib successfully induced hematologic, cytogenetic and molecular remission of Ph ALL, and restored complete donor chimerism, along with controllable GvHD.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Prognosis
/
Stem Cells
/
Thrombocytopenia
/
Tissue Donors
/
Protein-Tyrosine Kinases
/
Philadelphia Chromosome
/
Cyclosporine
/
Mesylates
/
Cytogenetics
/
Stem Cell Transplantation
Type of study:
Prognostic study
Limits:
Child
/
Humans
/
Male
Language:
Korean
Journal:
Korean Journal of Pediatric Hematology-Oncology
Year:
2003
Type:
Article
Similar
MEDLINE
...
LILACS
LIS